Kamada Ltd (KMDA) 4.23 $KMDA
Quarterly Report Card: New Research on Cisco, PepsiCo, Akamai, Team Health Holdings, and Kamada
PR Newswire - Thu Feb 12, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AKAM: 68.77 (+1.18), KMDA: 4.23 (+0.03), TMH: 59.69 (-0.19), CSCO: 29.43 (-0.03), PEP: 99.13 (-1.14)
Kamada ups EPS 25% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:12AM CST
KMDA: 4.23 (+0.03)
Kamada misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:38AM CST
KMDA: 4.23 (+0.03)
Kamada Reports 2014 Fourth Quarter and Full Year Financial Results
Business Wire - Wed Feb 11, 6:01AM CST
--Conference call begins today at 8:30 a.m. Eastern time
KMDA: 4.23 (+0.03)
Kamada reports February 11, reaffirms revenue guidance
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 10:19AM CST
KMDA: 4.23 (+0.03)
Kamada Affirms 2014 Revenue Guidance
Business Wire - Thu Feb 05, 9:11AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today affirms 2014 revenue guidance and announces that the Company will release financial results for the three and twelve months ended December 31, 2014 prior to the market open on Wednesday, February 11, 2015.
KMDA: 4.23 (+0.03)
Kamada Reports Encouraging Interim Data from its Phase 1/2 Extension Study: AAT in Pediatric Patients with Type 1 Diabetes
Business Wire - Mon Feb 02, 7:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today reported additional data from the Company's ongoing extension study of its open-label Phase 1/2 clinical trial with its lead product, intravenous Alpha1-Proteinase Inhibitor-Human (AAT), to treat recently diagnosed type 1 diabetes (T1D) pediatric patients . Treatment of T1D patients with Kamada's AAT may have several medical benefits including slowing the progression of the disease, improved metabolic control, reduction of daily insulin dose requirements, and most importantly, reduction of diabetes complications.
KMDA: 4.23 (+0.03)
Can John Paulson Bounce Back in 2015? Investments in Health Care and Pharmaceuticals Could Help
at The Street - Mon Jan 12, 8:31AM CST
Billionaire investor John Paulson's portfolio took a beating in 2014. A look at his equities holdings reveals why.
KOG: 6.56 (-0.39), ANV: 0.97 (-0.03), WLL: 38.53 (+2.41), VRX: 167.00 (-0.50), NCQ: 0.56 (+0.03), VNDA: 12.37 (unch), FDO: 77.86 (+0.31), VOD: 35.85 (+0.14), CIE: 8.90 (+0.20), AGN: 229.49 (+1.87), S: 5.23 (+0.08), SHPG: 239.82 (+6.11), AOL: 41.78 (+1.22), KMDA: 4.23 (+0.03), ABBV: 58.05 (+1.00), DG: 68.82 (+1.23), TWC: 149.74 (+2.21), TMUS: 31.75 (+0.16), VZ: 49.31 (-0.21), CMCSA: 59.47 (+1.09), OAS: 16.84 (-0.03)
Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD
Business Wire - Wed Jan 07, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today provides a clinical/regulatory update.
KMDA: 4.23 (+0.03)
Kamada set for gap up at the open
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:43AM CST
KMDA: 4.23 (+0.03)
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting
Business Wire - Thu Dec 11, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that interim data from a Phase I/II clinical study of the Company's proprietary human Alpha-1 Antitrypsin (AAT) conducted by the Fred Hutchinson Cancer Research Center in Seattle, Washington, for the treatment of graft-versus-host-disease (GvHD) were highlighted in a poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition that was held from December 6-9, 2014 in San Francisco.
KMDA: 4.23 (+0.03)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 70.00 (+0.69), KOG: 6.56 (-0.39), MEAS: 86.00 (+0.01), HHC: 144.41 (+6.41), AET: 96.12 (-0.96), DLPH: 78.70 (+0.64), DLTR: 76.82 (+0.97), AEM: 32.61 (+0.10), AUXL: 36.47 (-0.06), DG: 68.82 (+1.23), ABBV: 58.05 (+1.00), DXM: 7.08 (-0.03), MNK: 115.01 (+2.51), ATHL: 58.40 (unch), NCQ: 0.56 (+0.03), COV: 106.71 (-1.36), AU: 12.33 (+0.36), MYL: 55.85 (+1.34), IAG: 2.23 (-0.08), FDO: 77.86 (+0.31), MGM: 21.46 (+0.22), GNW: 8.67 (+0.17), HIG: 41.27 (+0.19), NG: 3.96 (+0.03), EQIX: 227.70 (-0.04), HSH: 62.96 (unch), OAS: 16.84 (-0.03), PETM: 82.70 (+0.03), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), BPOP: 33.07 (+0.01), ENZY: 5.68 (-0.02), FCX: 20.29 (+0.82), GFI: 4.83 (-0.21), CZR: 10.78 (+0.18), CVC: 20.60 (+0.32), CIE: 8.90 (+0.20), CACQ: 7.72 (+0.12), AGN: 229.49 (+1.87), ECA: 14.07 (+0.37), FCH: 10.55 (+0.01), R: 93.92 (+0.41), DTV: 87.51 (-0.32), KMDA: 4.23 (+0.03), ANV: 0.97 (-0.03), MOVE: 20.95 (-0.03), BAC: 16.61 (-0.06), GRFS: 34.65 (+0.28), POST: 48.62 (-0.25), HCA: 68.54 (-0.48), RDN: 16.10 (-0.43), BEE: 13.16 (-0.23), CPWR: 10.35 (+0.01), GLD: 117.98 (+0.64), RLGY: 48.86 (+0.52), MTG: 9.18 (+0.07), HMHC: 19.98 (-0.09), CMCSA: 59.47 (+1.09), CBS: 59.83 (+2.06), BABA: 89.05 (+1.95)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 8.80 (+0.40), KMDA: 4.23 (+0.03), VBIV: 3.01 (+0.01), NNVC: 2.97 (-0.05), SVA: 5.05 (+0.06)
Kamada set for gap down at the open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:47AM CST
KMDA: 4.23 (+0.03)
Kamada Adj. Net loss of $1.9M, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:40AM CST
KMDA: 4.23 (+0.03)
Kamada Announces Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 6:01AM CST
--Conference Call Begins Today at 8:30 a.m. Eastern Time
KMDA: 4.23 (+0.03)
Kamada reports November 12
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:44AM CST
KMDA: 4.23 (+0.03)
Kamada to Host Third Quarter 2014 Financial Results Conference Call on November 12, 2014
Business Wire - Mon Nov 10, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and nine months ended September 30, 2014 prior to the market open on Wednesday, November 12, 2014.
KMDA: 4.23 (+0.03)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 391.66 (-0.45), PCYC: 163.28 (+0.23), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), ALDR: 26.06 (+0.18), IDRA: 4.10 (-0.14), SGEN: 31.57 (+0.36), JAZZ: 169.69 (+6.89), ALXN: 182.29 (+6.02), KMDA: 4.23 (+0.03), ATHX: 2.12 (unch), NVS: 102.20 (-0.17)
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease
Business Wire - Wed Oct 29, 7:36AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat Graft-versus-host-disease (GVHD). Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
KMDA: 4.23 (+0.03)
Quarterly Report Card: New Research on Cisco, PepsiCo, Akamai, Team Health Holdings, and Kamada
PR Newswire - Thu Feb 12, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AKAM: 68.77 (+1.18), KMDA: 4.23 (+0.03), TMH: 59.69 (-0.19), CSCO: 29.43 (-0.03), PEP: 99.13 (-1.14)
Kamada ups EPS 25% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:12AM CST
KMDA: 4.23 (+0.03)
Kamada misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:38AM CST
KMDA: 4.23 (+0.03)
Kamada Reports 2014 Fourth Quarter and Full Year Financial Results
Business Wire - Wed Feb 11, 6:01AM CST
--Conference call begins today at 8:30 a.m. Eastern time
KMDA: 4.23 (+0.03)
Kamada reports February 11, reaffirms revenue guidance
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 10:19AM CST
KMDA: 4.23 (+0.03)
Kamada Affirms 2014 Revenue Guidance
Business Wire - Thu Feb 05, 9:11AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today affirms 2014 revenue guidance and announces that the Company will release financial results for the three and twelve months ended December 31, 2014 prior to the market open on Wednesday, February 11, 2015.
KMDA: 4.23 (+0.03)
Kamada Reports Encouraging Interim Data from its Phase 1/2 Extension Study: AAT in Pediatric Patients with Type 1 Diabetes
Business Wire - Mon Feb 02, 7:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today reported additional data from the Company's ongoing extension study of its open-label Phase 1/2 clinical trial with its lead product, intravenous Alpha1-Proteinase Inhibitor-Human (AAT), to treat recently diagnosed type 1 diabetes (T1D) pediatric patients . Treatment of T1D patients with Kamada's AAT may have several medical benefits including slowing the progression of the disease, improved metabolic control, reduction of daily insulin dose requirements, and most importantly, reduction of diabetes complications.
KMDA: 4.23 (+0.03)
Can John Paulson Bounce Back in 2015? Investments in Health Care and Pharmaceuticals Could Help
at The Street - Mon Jan 12, 8:31AM CST
Billionaire investor John Paulson's portfolio took a beating in 2014. A look at his equities holdings reveals why.
KOG: 6.56 (-0.39), ANV: 0.97 (-0.03), WLL: 38.53 (+2.41), VRX: 167.00 (-0.50), NCQ: 0.56 (+0.03), VNDA: 12.37 (unch), FDO: 77.86 (+0.31), VOD: 35.85 (+0.14), CIE: 8.90 (+0.20), AGN: 229.49 (+1.87), S: 5.23 (+0.08), SHPG: 239.82 (+6.11), AOL: 41.78 (+1.22), KMDA: 4.23 (+0.03), ABBV: 58.05 (+1.00), DG: 68.82 (+1.23), TWC: 149.74 (+2.21), TMUS: 31.75 (+0.16), VZ: 49.31 (-0.21), CMCSA: 59.47 (+1.09), OAS: 16.84 (-0.03)
Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD
Business Wire - Wed Jan 07, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today provides a clinical/regulatory update.
KMDA: 4.23 (+0.03)
Kamada set for gap up at the open
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:43AM CST
KMDA: 4.23 (+0.03)
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting
Business Wire - Thu Dec 11, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that interim data from a Phase I/II clinical study of the Company's proprietary human Alpha-1 Antitrypsin (AAT) conducted by the Fred Hutchinson Cancer Research Center in Seattle, Washington, for the treatment of graft-versus-host-disease (GvHD) were highlighted in a poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition that was held from December 6-9, 2014 in San Francisco.
KMDA: 4.23 (+0.03)
Tracking John Paulson's Paulson & Company Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Thu Nov 20, 12:49AM CST
RKT: 70.00 (+0.69), KOG: 6.56 (-0.39), MEAS: 86.00 (+0.01), HHC: 144.41 (+6.41), AET: 96.12 (-0.96), DLPH: 78.70 (+0.64), DLTR: 76.82 (+0.97), AEM: 32.61 (+0.10), AUXL: 36.47 (-0.06), DG: 68.82 (+1.23), ABBV: 58.05 (+1.00), DXM: 7.08 (-0.03), MNK: 115.01 (+2.51), ATHL: 58.40 (unch), NCQ: 0.56 (+0.03), COV: 106.71 (-1.36), AU: 12.33 (+0.36), MYL: 55.85 (+1.34), IAG: 2.23 (-0.08), FDO: 77.86 (+0.31), MGM: 21.46 (+0.22), GNW: 8.67 (+0.17), HIG: 41.27 (+0.19), NG: 3.96 (+0.03), EQIX: 227.70 (-0.04), HSH: 62.96 (unch), OAS: 16.84 (-0.03), PETM: 82.70 (+0.03), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), BPOP: 33.07 (+0.01), ENZY: 5.68 (-0.02), FCX: 20.29 (+0.82), GFI: 4.83 (-0.21), CZR: 10.78 (+0.18), CVC: 20.60 (+0.32), CIE: 8.90 (+0.20), CACQ: 7.72 (+0.12), AGN: 229.49 (+1.87), ECA: 14.07 (+0.37), FCH: 10.55 (+0.01), R: 93.92 (+0.41), DTV: 87.51 (-0.32), KMDA: 4.23 (+0.03), ANV: 0.97 (-0.03), MOVE: 20.95 (-0.03), BAC: 16.61 (-0.06), GRFS: 34.65 (+0.28), POST: 48.62 (-0.25), HCA: 68.54 (-0.48), RDN: 16.10 (-0.43), BEE: 13.16 (-0.23), CPWR: 10.35 (+0.01), GLD: 117.98 (+0.64), RLGY: 48.86 (+0.52), MTG: 9.18 (+0.07), HMHC: 19.98 (-0.09), CMCSA: 59.47 (+1.09), CBS: 59.83 (+2.06), BABA: 89.05 (+1.95)
Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 8.80 (+0.40), KMDA: 4.23 (+0.03), VBIV: 3.01 (+0.01), NNVC: 2.97 (-0.05), SVA: 5.05 (+0.06)
Kamada set for gap down at the open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:47AM CST
KMDA: 4.23 (+0.03)
Kamada Adj. Net loss of $1.9M, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:40AM CST
KMDA: 4.23 (+0.03)
Kamada Announces Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 6:01AM CST
--Conference Call Begins Today at 8:30 a.m. Eastern Time
KMDA: 4.23 (+0.03)
Kamada reports November 12
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:44AM CST
KMDA: 4.23 (+0.03)
Kamada to Host Third Quarter 2014 Financial Results Conference Call on November 12, 2014
Business Wire - Mon Nov 10, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and nine months ended September 30, 2014 prior to the market open on Wednesday, November 12, 2014.
KMDA: 4.23 (+0.03)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 391.66 (-0.45), PCYC: 163.28 (+0.23), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), ALDR: 26.06 (+0.18), IDRA: 4.10 (-0.14), SGEN: 31.57 (+0.36), JAZZ: 169.69 (+6.89), ALXN: 182.29 (+6.02), KMDA: 4.23 (+0.03), ATHX: 2.12 (unch), NVS: 102.20 (-0.17)
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease
Business Wire - Wed Oct 29, 7:36AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat Graft-versus-host-disease (GVHD). Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
KMDA: 4.23 (+0.03)
